IPO

Bitdeer reports a massive 339% surge in Bitcoin mining while aggressively expanding its AI cloud services with cutting-edge NVIDIA GB200 GPUs.

The investment firm celebrated a strong 2025 with shareholder payouts, fueled by profitable exits and a new major investment in AI infrastructure firm TensorWave.

Mezo is offering token rewards to lure over $11B in wrapped Bitcoin from Ethereum, aiming to build a native Bitcoin DeFi ecosystem and fulfill a long-held vision.

California's Golden 1 Credit Union isn't just growing; it's winning top national awards for both business and culture. What's their secret?

Just weeks after a blockbuster IPO, travel tech firm Navan is under investigation for misleading investors as its stock plummets and its CFO departs.

The clean-energy firm is commercializing its tech, securing a 10-year fuel deal in Portugal and deploying rail turbines as it seeks greater market access.

Following a major tech acquisition, AppYea appoints the platform's original architect as CTO, aiming for regulated markets and a potential Nasdaq uplisting.

A tech firm is leveraging sound waves to overcome key hurdles in brain-computer interfaces, paving the way for advanced rehabilitation and assistive care.

Progyny signals better-than-expected 2025 results on robust member engagement, sparking analyst upgrades and sending its stock soaring ahead of a key conference.

The wellness firm secured a cash infusion by repricing options, a move that provides vital funds for its Zola brand but raises questions about dilution.

Carlsmed's AI-driven aprevo® platform shows massive surgeon adoption and market growth, signaling a new era of personalized, cost-effective spine care.

A new study reveals payment failures cost billions as customer patience runs out in minutes, creating a crisis for retail and hospitality brands.

After a strategic pivot reverses a year of decline, Allurion's preliminary results show new growth. All eyes are now on the FDA for its 'procedureless' gastric balloon.

Erasca reports promising early data for its pan-RAS inhibitor, ERAS-0015, showing tumor shrinkage at low doses and shaking up the competitive landscape.

The genomics leader posted a 41% revenue surge in 2025 and projects profitability, yet its stock tumbled on what some see as conservative 2026 guidance.

V2X secures a major contract under the MDA's SHIELD program, positioning it to shape the future of America's layered defense with advanced tech.

BioXcel Therapeutics is pushing its drug IGALMI® for home use, a move that could transform mental healthcare but carries significant financial and safety risks.

With a key FDA filing and pivotal data on the horizon, Pharvaris aims to redefine HAE treatment with its convenient, rapid-acting oral therapy.

Amid rising costs and market volatility, Malaysia's top SMEs are redefining success. The SME100 Awards reveal how innovation fuels their remarkable growth.

Vallourec's significant contract win for Shell's Orca project signals the enduring strategic value of Brazil's deepwater reserves and advanced tech.